Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation

Xiao-qing XU; Wen-qi DENG; Da-yang WANG; Meng LI; Dong-lei KOU; Pei-tong ZHANG

doi:10.1007/s11655-020-3197-1

Your Location：

Home >

Browse articles >

Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation

Clinical Experience | Updated：2021-09-01

- Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation
- Chinese Journal of Integrative Medicine Vol. 27, Issue 7, Pages: 496-501(2021)
- Affiliations：
  
  1.Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing (100053), China
  2.Graduate School, Beijing University of Chinese Medicine, Beijing (100029), China
- Author bio：
  
  Prof. ZHANG Pei-tong, E-mail:drzhangpeitong@hotmail.com
- Funds：
- DOI：10.1007/s11655-020-3197-1
  CLC：
- Published：01 July 2021，
  
  Published Online：04 June 2020，
  
  Accepted：13 March 2020
Scan for full text
Xiao-qing XU, Wen-qi DENG, Da-yang WANG, et al. Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation. [J]. Chinese Journal of Integrative Medicine 27(7):496-501(2021)
DOI：

Xiao-qing XU, Wen-qi DENG, Da-yang WANG, et al. Chinese Medicine Treatment Prolonged Survival in Small Cell Lung Cancer Patients: A Clinical Observation. [J]. Chinese Journal of Integrative Medicine 27(7):496-501(2021) DOI： 10.1007/s11655-020-3197-1.

摘要

Abstract

Objective:

To evaluate the effect of Chinese medicine (CM) treatment on survival time and quality of life (QOL) in patients with small cell lung cancer (SCLC).

Methods:

This was an exploratory and prospective clinical observation. Patients diagnosed with SCLC receiving CM treatment were included and followed up every 3 months. The primary outcome was overall survival (OS)

and the secondary outcomes were progression-free survival (PFS) and QOL.

Results:

A total of 136 patients including 65 limited-stage SCLC (LS-SCLC) patients and 71 extensivestage SCLC (ES-SCLC) patients were analyzed. The median OS of ES-SCLC patients was 17.27 months

and the median OS of LS-SCLC was 40.07 months. The survival time was 16.27 months for SCLC patients with brain metastasis

9.83 months for liver metastasis

13.43 months for bone metastasis

and 18.13 months for lung metastasis. Advanced age

pleural fluid

liver and brain metastasis were risk factors

while longer CM treatment duration was a protective factor. QOL assessment indicated that after 6 months of CM treatment

scores increased in function domains and decreased in symptom domains.

Conclusion:

CM treatment might help prolong OS of SCLC patients. Moreover

CM treatment brought the trend of symptom amelioration and QOL improvement. These results provide preliminary evidence for applying CM in SCLC multi-disciplinary treatment.

关键词

Keywords

small cell lung cancerChinese medicinesurvival timefollow-upquality of life

references

X Zou, M Jia, X Wang, X Zhi. Changing epidemic of lung cancer &tobacco and situation of tobacco control in China. Chin J Lung Cancer(Chin) 2017;20:505-510.

A Tartarone, P Giordano, R Lerose, MG Rodriquenz, R Conca, M Aieta. Progress and challenges in the treatment of small cell lung cancer. Med Oncol 2017;34:110.

TE Stinchcombe. Current treatments for surgically resectable, limited-stage, and extensive-stage small cell lung cancer. Oncologist 2017;22:1510-1517.

LA Byers, CM Rudin. Small cell lung cancer: where do we go from here? Cancer 2015;121:664-672.

M Parikh, J Riess, Lara PNJr. New and emerging developments in extensive-stage small cell lung cancer therapeutics. Curr Opin Oncol 2016;28:97-103.

N Baize, I Monnet, L Greillier, G Quere, M Kerjouan, H Janicot, et al. Second-line treatments of small-cell lung cancers. Expert Rev Anticancer Ther 2017;17:1033-1043.

JP van Meerbeeck, DA Fennell, DK De Ruysscher. Small-cell lung cancer. Lancet 2011;378:1741-1755.

K Nosaki, T Seto. The role of radiotherapy in the treatment of small-cell lung cancer. Curr Treat Options Oncol 2015;16:56.

F Qi, L Zhao, A Zhou, B Zhang, A Li, Z Wang, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015;9:16-34.

YH Liao, CI Li, CC Lin, JG Lin, JH Chiang, TC Li. Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients. J Cancer Res Clin Oncol 2017;143:2425-2435.

WR Tang, SH Yang, CT Yu, CC Wang, ST Huang, TH Huang, et al. Long-term effectiveness of combined treatment with traditional chinese medicine and western medicine on the prognosis of patients with lung cancer. J Altern Complement Med 2016;22:212-222.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) small cell lung cancer(Version 1. 2015). Fort Washington; 2015.

T Sun, XY Chen. Study on TCM syndrome characteristics of patients with primary small cell lung cancer before and after chemotherapy.China J Tradit Chin Med Pharm (Chin) 2002;17:378-379.

ZW Wang, JY Wang, J Hu, CQ Liu, Q Wu, J Yan, et al. Association between traditional Chinese medicine syndrome elements before radiotherapy and radiation-induced lung injury in lung cancer patietns: a prospective cohort study. Liaoning J Tradit Chin Med(Chin) 2019;46:1233-1236.

MX Guo, C Wu, WH Tong. Research progress in equivalence study of TCM dispensing granule and traditional herbal decoction. Modern Chin Med (Chin) 2016;18:1107-1110.

YD Zhao, HJ Ye. Review of pharmacodynamics equivalence between decotion pieces and formula granules of traditional Chinese medicine. J Liaoning Univ Tradit Chin Med (Chin) 2010;12:227-229.

NK Aaronson, S Ahmedzai, B Bergman, M Bullinger, A Cull, NJ Duez, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.

B Bergman, NK Aaronson, S Ahmedzai, S Kaasa, M Sullivan. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994;30a:635-642.

B Xia, LZ Hong, XW Cai, ZF Zhu, Q Liu, KL Zhao, et al. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2015;91:517-523.

W Zhang, H Zhu, Z Zhou, Q Feng, D Chen, H Zhang, et al.Clinical outcomes and prognostic factors in limited-stage small cell lung cancer: a single institution experience. Chin J Oncol (Chin)2015;37:223-226.

L Zhou, Z Xie, Z Shao, W Chen, H Xie, X Cui, et al. Modeling the relationship between baseline lactate dehydrogenase and prognosis in patients with extensive-disease small cell lung cancer:a retrospective cohort study. J Thorac Dis 2018;10:1043-1049.

T Qin, N Zhou, YD Zeng, X Dinglin, Y Zhao, H Liu, et al. Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. Onco Targets Ther 2016;9:1095-1103.

AA Elegbede, AJ Gibson, H Fu, ML Dean, DA Ezeife, H Lau, et al.Real-world adherence to guideline-recommended treatment for small cell lung cancer. Am J Clin Oncol 2019;43:1.

H Ogino, M Hanibuchi, S Kakiuchi, A Saijo, T Tezuka, Y Toyoda, et al. Analysis of the prognostic factors of extensive disease small-cell lung cancer patients in Tokushima University Hospital. J Med Invest 2016;63:286-293.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Qishen Taohong Granule as Adjuvant Therapy for Improving Cardiac Function and Quality of Life in Patients with Chronic Heart Failure: A Randomized Controlled Trial

Development of Improved Version of Quality of Life Assessment Instrument for Lung Cancer Patients Based on Traditional Chinese Medicine (QLASTCM-Lu)

Impact of Jumihaidokuto (Shi-Wei-Bai-Du-Tang) on Treatment of Chronic Spontaneous Urticaria: A Randomized Controlled Study

Chemical Composition, Pharmacological Effects and Clinical Applications of Cinobufacini

Immunomodulatory Function of Pien Tze Huang in T Cell-Mediated Anti-tumor Activity against B16-F10, MC38 and Hep1-6 Tumor Models

Related Author

No data

Related Institution

Department of Graduate School, Beijing University of Chinese Medicine

Department of Cardiology, Dong Fang Hospital, Beijing University of Chinese Medicine

Department of Cardiology,Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Cardiology,Dongzhimen Hospital, Beijing University of Chinese Medicine

Department of Traditional Chinese Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰